keine Finanzberatung

MRK · Merck & Co., Inc.

US pharma giant built around the Keytruda cancer franchise

Risiko 5/10 · MODERATE RISK · Patent-cliff pharma · $150.33 ▼ 1.32%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $150.33
  • Market cap $370.9B
  • P/E (ttm) 120.26
  • Div yield 2.23%
  • 52-wk range $77.58 – $156.92
  • Index rank #37 / —

Wichtigste Risiken

  • Keytruda patent cliff (Shareholders) — HIGH
  • Pipeline readouts disappoint (Shareholders) — MED
  • US drug-price negotiation squeezes margins (Shareholders) — MED
  • Product-safety litigation (Customers) — LOW

Fazit

Cheap on forward earnings only if the pipeline delivers before Keytruda's cliff.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.